Pharmabiz2h
Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary
Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary: Our Bureau, Mumbai Tuesday, January 7, 2025, 17:15 Hrs [IST] Zydus L ...
Pharmabiz2h
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection: Staten Island, New York Tuesday, January 7, 2025, 18:00 ...
Pharmabiz3h
SunAct Cancer Institute ties up with Singapore’s CytoMed for phase 2 clinical trials on innovative Gamma Delta T-cell cancer therapy in India
Our Bureau, Mumbai Tuesday, January 7, 2025, 16:45 Hrs [IST] ...
Pharmabiz3h
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease: Hyogo, Japan Tuesday, January 7, 20 ...
Pharmabiz4h
US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease
US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease: Aarhus, Denmark Tuesday, January 7, 2025, 16:00 Hrs [IST] NMD Ph ...
Pharmabiz4h
RNT Health Insights receives second US FDA breakthrough device designation for esophageal cancer detection tool
RNT Health Insights receives second US FDA breakthrough device designation for esophageal cancer detection tool: Our Bureau, Mumbai Tuesday, January 7, 2025, 15:40 Hrs [IST] RNT H ...
Pharmabiz5h
eMBR Genomics partners with Axio BioPharma to make MKLP1 Pro antibodies commercially available
MBR Genomics partners with Axio BioPharma to make MKLP1 Pro antibodies commercially available: Madison, Wisconsin Tuesday, January 7, 2025, 15:00 Hrs [IST] In a milestone for cel ...
Pharmabiz6h
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...
Pharmabiz12h
Indian pharma notes revised Schedule M extension signals key step to avoid closure of units
Indian pharma notes revised Schedule M extension signals key step to avoid closure of units: Nandita Vijayasimha, Bengaluru Tuesday, January 7, 2025, 08:00 Hrs [IST] Indian pharma ...
Pharmabiz9h
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...
Pharmabiz10h
CHOP researchers develop new tool with potential to advance precision medicine treatment for cancer
CHOP researchers develop new tool with potential to advance precision medicine treatment for cancer: Philadelphia, Pennsylvania Tuesday, January 7, 2025, 10:00 Hrs [IST] Researche ...
Pharmabiz11h
Astellas Pharma’s Vyloy receives China NMPA approval for first-line treatment of advanced gastric or GEJ adenocarcinoma
Astellas Pharma’s Vyloy receives China NMPA approval for first-line treatment of advanced gastric or GEJ adenocarcinoma: Tokyo Tuesday, January 7, 2025, 09:00 Hrs [IST] Astellas ...